Conclusion

Overall, the present case suggests that some NSCLC patients who develop a spectrum of cutaneous toxicities might have a good tumor response using erlotinib monotherapy. Our findings provide a method for clinicians to predict erlotinib efficacy in NSCLC therapy without knowledge of the EGFR mutation status. At a time when treatment is increasingly targeting tumor types and patients, exploring the connection between cutaneous toxicities and tumor response may aid in the identification of new clinical markers for treatment efficacy. Currently, for most of the reported studies, the primary outcome parameter was either response to therapy or overall survival. Reporting of toxicities was a secondary aim; thus, data collection has largely been obtained secondarily.18Therefore, there is lack of data in the literature on the frequency of cutaneous toxicities (in general) in non-responders compared to responders to EGFR inhibitor therapy. Future large-scale studies are needed to validate these findings.


Disclosure


Continue Reading

The authors have no conflict of interest to disclose.


Feng Jin,1 Hui Zhu,2 Li Kong,2 Jinming Yu2

1Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan, Jinan, People’s Republic of China; 2Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, People’s Republic of China


References

1. Lucchini E, Pilotto S, Spada E, Melisi D, Bria E, Tortora G. Targeting the epidermal growth factor receptor in solid tumors: focus on safety. Expert Opin Drug Saf. 2014;13(5):535–549.

2. Gutzmer R, Wollenberg A, Ugurel S, Homey B, Ganser A, Kapp A. Cutaneous side effects of new antitumor drugs: clinical features and management. Dtsch Arztebl Int. 2012;109(8):133–140.

3. Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19(8): 1079–1095.

4. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7): 491–500.

5. Borkar DS, Lacouture ME, Basti S. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer. 2013;21(4):1167–1174.

6. Smith J. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clin Ther.2005;27(10):1513–1534.

7. Heidary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol.2008;58(4):545–570.

8. Rosman IS, Anadkat MJ. Tufted hair folliculitis in a woman treated with trastuzumab. Targ Oncol.2010;5(4):295–296.

9. Keefe DM, Bateman EH. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol. 2012;9(2):98–109.

10. Lacouture ME, Lai SE. The PRIDE (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol.2006;155(4):852–854.

11. Liu HB, Wu Y, Lv TF, et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One.2013;8(1):e55128.

12. Faehling M, Eckert R, Kuom S, Kamp T, Stoiber KM, Schumann C. Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line. Oncology. 2010;78(3–4):249–258.

13. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park). 2003;17(11 Suppl 12):23–28.

14. Carser JE, Summers YJ. Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer. J Thorac Oncol. 2006;1(9):1040–1041.

15. Brandi G, Venturi M, Dika E, Maibach H, Patrizi A, Biasco G. Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy. Cutan Ocul Toxicol. 2013;32(4):336–338.

16. Chanprapaph K, Vachiramon V, Rattanakaemakorn P. Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management. Dermatol Res Pract. 2014;2014:734249.

17. Rudin CM, Liu W, Desai A, et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol. 2008;26(7):1119–1127.

18. Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol.2007;25(26):4096–4103.

Source: OncoTargets and Therapy.
Originally published on April 23, 2015.